-
- (-%)
Vallon Pharmaceuticals, Inc. [GRI]
Source:
Company Overview
Vallon Pharmaceuticals, Inc primarily focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. Our lead investigational product candidate, ADAIR, was a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine which was being developed for the treatment of attention-deficit/hyperactivity disorder and narcolepsy.
Country | United States |
Headquarters | la jolla, california |
Phone Number | (619) 400-1171 |
Industry | |
CEO | David Baker |
Website | vallon-pharma.com |